• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Cytokinetics Announces Interim Phase I Results for SB-743921 to Be Presented at the 2005 Annual Meeting of the American Society of Clinical Oncology

Posted on: Tuesday, 5 April 2005, 18:00 CDT

Cytokinetics, Inc. (Nasdaq: CYTK) announced today that interim results of a Phase I study for SB-743921 being conducted by GlaxoSmithKline (GSK) will be presented at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. The poster presentation will highlight data relating to the safety, tolerability and pharmacokinetics of SB-743921, a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin protein essential for proper cell division. SB-743921 is the second drug candidate in clinical development that has arisen from a broad strategic collaboration between Cytokinetics and GSK to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases.

In 2003, GSK initiated a broad clinical trials program for the first drug candidate arising from this program, SB-715992. GSK is currently evaluating SB-715992 in a broad clinical trials program with Phase II studies being conducted in non-small cell lung, ovarian and breast cancers and Phase Ib clinical trials underway to evaluate SB-715992 in combination with docetaxel, carboplatin and capecitabine. Data from two Phase I studies designed to evaluate the safety, tolerability and pharmacokinetics of SB-715992 were presented at ASCO in 2004. In addition to the ongoing studies being conducted by GSK, the National Cancer Institute (NCI) plans to enroll patients in 2005 in six other Phase II clinical trials evaluating SB-715992 in other tumor types, including renal cell carcinoma, melanoma, head and neck, hepatocellular, colorectal and prostate cancers, and in two other Phase I trials in leukemia and advanced solid tumors.

Poster Presentation and Discussion at ASCO

The following abstract will be presented at ASCO and will be available through the ASCO website (www.asco.org) prior to the meeting:

Abstract # 2010: Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor. (Poster presentation by Kyle D. Holen, Univ. of Wisconsin Comprehensive Cancer Center, Madison, WI, on Saturday, May 14, 2004, Developmental Therapeutics: Cytotoxic Chemotherapy; Poster Display, Level 3, 314A, 8:00 AM - 11:00 AM and Poster Discussion, Level 3, 307A, 10:00 AM - 11:00 AM).

About Cytokinetics

Cytokinetics is a leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics' focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease and other diseases. Cytokinetics has developed a cell biology driven approach and proprietary technologies to evaluate the function of many interacting proteins in the complex environment of the intact human cell. Cytokinetics employs the PUMA(TM) system and Cytometrix(TM) technologies to enable early identification and automated prioritization of compounds that are highly selective for their intended protein targets without other cellular effects, and are thereby less likely to give rise to clinical side effects. Cytokinetics and GlaxoSmithKline have entered into a strategic alliance to discover, develop and commercialize small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. GlaxoSmithKline is conducting Phase II and Phase Ib clinical trials for SB-715992 and a Phase I clinical trial for SB-743921, each a drug candidate that has emerged from the strategic alliance. Cytokinetics' heart failure program is the second program to leverage the company's expertise in cytoskeletal pharmacology. Cytokinetics expects to enter human clinical trials in 2005 with a novel small molecule cardiac myosin activator for the treatment of heart failure. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to the expected timing, scope and results of our clinical development and research program, including Company milestones for 2005, initiation of clinical trials, and statements regarding the potential benefits of our drug candidates and potential drug candidates and the enabling capabilities of our proprietary technologies. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of Cytokinetics' drug candidates that could slow or prevent clinical development, product approval or market acceptance (including the risks relating to uncertainty of patent protection for Cytokinetics' intellectual property or trade secrets, Cytokinetics' ability to obtain additional financing if necessary and unanticipated research and development and other costs). For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Source: Business Wire

More News in this Category